Cumberland Pharmaceuticals Q1 FY26 net loss widens to $3.3 million; revenue falls 22% to $9.1 million

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX

0.00
  • Cumberland Pharmaceuticals posted Q1 2026 net loss attributable to common shareholders of USD 3.29 million, swinging from profit a year earlier.
  • Net revenues fell to USD 9.13 million, while operating loss widened to USD 3.13 million.
  • Total operating expenses climbed to USD 12.3 million as selling and marketing rose to USD 5.06 million.
  • Company announced a strategic transaction with Apotex for USD 100 million in cash consideration for its portfolio of FDA-approved brands, pending shareholder approval and other closing conditions.
  • Pipeline update highlighted FDA Fast Track designation for ifetroban in Duchenne muscular dystrophy, with top-line Phase II results in systemic sclerosis next milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL52083) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.